Paper Details

  1. Home
  2. Paper Details

Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.

Author: AhumadaA, CalvoM, CastellanoG, DevesaM J, Fernández-RodríguezC, Fernández-VázquezI, GonzálezR, HernándezE, Hernández-AlbujarA, IzquierdoS, LozanoM, Muñoz-GómezR, OrtizM, RincónD

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r)±dasabuvir (DSV)±ribavirin (RBV) for treating hepatitis C virus (HCV) infection in patients with severe kidney disease (CKD). The study found that the treatment was highly effective in patients with stage 4 or 5 CKD, with a 95.7% sustained virological response rate at 12 weeks. The treatment was generally well tolerated, with no severe adverse events linked to the antiviral therapy. While anemia was observed in some patients who received ribavirin, overall, the treatment was similar in efficacy to those with normal kidney function.
Paper Details　
Original Abstract of the Article :
Limited data are available on direct-acting antivirals for treating hepatitis C virus (HCV) infection in patients with severe renal impairment. The aim of this study was to evaluate the effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) &#...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jvh.12664

データ提供：米国国立医学図書館（NLM）

Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir for HCV in Severe Renal Impairment: A Multicenter Study

This study delves into the complex world of hepatitis C virus (HCV) treatment, specifically focusing on patients with severe renal impairment. Like a camel navigating a scorching desert, these patients often face additional challenges in their quest for effective treatment. This research explores the efficacy and safety of a combination antiviral therapy in this vulnerable patient population, providing valuable insights for clinicians and patients alike.

Navigating the Desert of HCV Treatment: A New Oasis for Renal Impairment

The study finds that the combination therapy of ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and well-tolerated in patients with severe renal impairment, offering a beacon of hope in the desert of HCV treatment challenges. The researchers observed high sustained virological response rates, suggesting that this therapy can effectively combat HCV infection even in patients with compromised kidney function. While the study acknowledges the potential for adverse events, particularly anemia associated with ribavirin use, it highlights the importance of careful monitoring and management to minimize potential risks.

HCV Treatment in Renal Impairment: A Path to Recovery

This research provides valuable guidance for clinicians treating HCV-infected patients with severe renal impairment. The findings suggest that this combination therapy offers a safe and effective path to recovery, paving the way for a more positive outlook for these patients. It's like finding a reliable camel caravan that can safely and effectively transport patients through the challenging desert of HCV treatment, ultimately leading them to a healthier and more fulfilling life.

Dr. Camel's Conclusion

This study offers a ray of hope for patients with HCV and severe renal impairment. The combination therapy of ombitasvir/paritaprevir/ritonavir plus dasabuvir provides an effective and safe treatment option, allowing these patients to navigate the desert of HCV infection and reach a destination of sustained virological response.
Date :
  1. Date Completed 2018-02-14
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

27976490

DOI: Digital Object Identifier

10.1111/jvh.12664

Related Literature

Article Analysis
・Side Effects of ombitasvir paritaprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.